Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605527 · ClinicalTrials.gov registry record
Understanding the Role of Genes and Biomarkers in the Inflammation and Blood Clotting Process in Children With Acute Lung Injury
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 396
- Enrollment target
NCT00605527: Completed study, sponsored by University of California, San Francisco.
NCT00605527 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 396 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00605527 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 396 participants
- Enrollment target
Study Summary
Acute lung injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition that causes respiratory failure. This study will examine if differences in genes and biomarkers involved in the inflammation and blood clotting process may affect the severity of and recovery from ALI/ARDS in children hospitalized with the condition.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2007-11 |
| Est. Completion | 2016-12 |
What the finished NCT00605527 record still lists
NCT00605527 is an observational study that tracks outcomes without assigning an intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00605527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00605527 about?
NCT00605527 is a clinical study titled "Understanding the Role of Genes and Biomarkers in the Inflammation and Blood Clotting Process in Children With Acute Lung Injury". Acute lung injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition that causes respiratory failure. This study will examine if differences in genes and biomarkers involved in the inflammation and blood clotting process may affect the severity of and recovery from ALI/ARDS ...
What is the current status of trial NCT00605527?
This trial is currently completed. The enrollment target is 396 participants. The study started on 2007-11. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT00605527?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia